Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48Oct 17, 2024
COVID-19 Vaccine
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Novavax
PR-M06-21-028Jun 22, 2021
COVID-19 Vaccine
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Novavax
PR-M05-21-001May 03, 2021
Fast Track
Novavax COVID-19 Vaccine Granted Fast Track Designation by U.S. FDA
Novavax
PR-M11-20-008Nov 10, 2020
COVID-19
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India
Novavax
PR-M09-20-NI-17Sep 15, 2020
Collaboration
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
Novavax
PR-M08-20-NI-19Aug 13, 2020
Funding
Novavax Announces $1.6 Billion Funding from Operation Warp Speed
Novavax
PR-M07-20-NI-006Jul 07, 2020
Partnership
Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
AGC Biologics
PR-M06-20-NI-008Jun 05, 2020
COVID-19 Vaccine
Novavax Expands Large-Scale Global Manufacturing Capacity for COVID-19 Vaccine
Novavax
PR-M05-20-NI-043May 29, 2020
Strategic Partnership
Novavax and Catalent Biologics Enter Strategic Partnershipto Expand Gene Therapy Footprint
Catalent Biologics
PR-M07-19-NI-001Jul 01, 2019